MNPR vs. ^GSPC

Last updated Apr 2, 2026

Compare and contrast key facts about Monopar Therapeutics Inc. (MNPR) and S&P 500 Index (^GSPC).

Performance

MNPR vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monopar Therapeutics Inc. (MNPR) and S&P 500 Index (^GSPC). The values are adjusted to include any dividend payments, if applicable.

MNPR vs. ^GSPC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
MNPR Monopar Therapeutics Inc.	-15.18%	196.82%	1,193.36%	-85.65%	-26.17%	-47.55%	-63.13%	-37.36%
^GSPC S&P 500 Index	-3.95%	16.39%	23.31%	24.23%	-19.44%	26.89%	16.26%	0.79%

Returns By Period

In the year-to-date period, MNPR achieves a -15.18% return, which is significantly lower than ^GSPC's -3.95% return.

MNPR

• 1D: 1.10%
• 1M: 3.59%
• YTD: -15.18%
• 6M: -34.63%
• 1Y: 65.69%
• 3Y*: 99.74%
• 5Y*: 12.24%
• 10Y*: —

^GSPC

• 1D: 0.72%
• 1M: -4.45%
• YTD: -3.95%
• 6M: -2.02%
• 1Y: 16.73%
• 3Y*: 16.96%
• 5Y*: 10.34%
• 10Y*: 12.24%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MNPR vs. ^GSPC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MNPR

MNPR Risk / Return Rank: 65
MNPR Sharpe Ratio Rank: 67
MNPR Sortino Ratio Rank: 70
MNPR Omega Ratio Rank: 65
MNPR Calmar Ratio Rank: 63
MNPR Martin Ratio Rank: 59

^GSPC

^GSPC Risk / Return Rank: 67
^GSPC Sharpe Ratio Rank: 63
^GSPC Sortino Ratio Rank: 64
^GSPC Omega Ratio Rank: 69
^GSPC Calmar Ratio Rank: 60
^GSPC Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MNPR vs. ^GSPC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and S&P 500 Index (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MNPR	^GSPC	Difference
Sharpe ratio Return per unit of total volatility	0.77	0.92	-0.15
Sortino ratio Return per unit of downside risk	1.63	1.41	+0.22
Omega ratio Gain probability vs. loss probability	1.19	1.21	-0.03
Calmar ratio Return relative to maximum drawdown	1.06	1.41	-0.35
Martin ratio Return relative to average drawdown	1.96	6.61	-4.65
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MNPR vs. ^GSPC - Sharpe Ratio Comparison

The current MNPR Sharpe Ratio is 0.77, which is comparable to the ^GSPC Sharpe Ratio of 0.92. The chart below compares the historical Sharpe Ratios of MNPR and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	MNPR	^GSPC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.77	0.92	-0.15
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.04	0.61	-0.57
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.68	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	0.46	-0.51

Correlation

The correlation between MNPR and ^GSPC is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Drawdowns

MNPR vs. ^GSPC - Drawdown Comparison

The maximum MNPR drawdown since its inception was -98.93%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for MNPR and ^GSPC.

Drawdown Indicators

	MNPR	^GSPC	Difference
Max Drawdown Largest peak-to-trough decline	-98.93%	-56.78%	-42.15%
Max Drawdown (1Y) Largest decline over 1 year	-49.16%	-12.14%	-37.02%
Max Drawdown (5Y) Largest decline over 5 years	-95.54%	-25.43%	-70.11%
Max Drawdown (10Y) Largest decline over 10 years	—	-33.92%	—
Current Drawdown Current decline from peak	-58.97%	-5.78%	-53.19%
Average Drawdown Average peak-to-trough decline	-81.05%	-10.75%	-70.30%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.55%	2.60%	+23.95%

Volatility

MNPR vs. ^GSPC - Volatility Comparison

Monopar Therapeutics Inc. (MNPR) has a higher volatility of 14.03% compared to S&P 500 Index (^GSPC) at 5.37%. This indicates that MNPR's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MNPR	^GSPC	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.03%	5.37%	+8.66%
Volatility (6M) Calculated over the trailing 6-month period	48.30%	9.55%	+38.75%
Volatility (1Y) Calculated over the trailing 1-year period	86.58%	18.33%	+68.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	295.98%	16.90%	+279.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	268.32%	18.05%	+250.27%